VX 985

Drug Profile

VX 985

Alternative Names: VX-985

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Vertex Pharmaceuticals
  • Class Antivirals
  • Mechanism of Action Hepatitis C protease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 01 May 2014 Discontinued - Phase-I for Hepatitis C in USA (PO)
  • 22 Oct 2010 Vertex Pharmaceuticals completes enrolment in its Phase-I trial [NCT01144936] for Hepatitis C in USA
  • 06 Jul 2010 Phase-I clinical trials in Hepatitis C in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top